Form 4: Contineum Therapeutics Chief Scientific Officer Sells Shares Under 10b5-1 Plan

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 1,010 shares of Class A Common Stock at an average price of $16.0172, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Daniel S. Lorrain, the Chief Scientific Officer of Contineum Therapeutics, sold 1,010 shares of Class A Common Stock.
• The sale occurred on November 25, 2024, at a weighted average price of $16.0172 per share.
• The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on August 19, 2024.
• The shares were sold in multiple transactions with prices ranging from $16.00 to $16.14.
• Following the transaction, Mr. Lorrain directly owns 168,562 shares and indirectly owns 3,898 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for an insider stock sale under a pre-arranged plan, which is neither positive nor negative.

Industry Context

This is a routine filing for insider transactions and is common for executives who have pre-arranged trading plans to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate executives to manage their stock sales and avoid potential insider trading issues.
• The reported transaction is consistent with standard SEC Form 4 filings for insider stock sales.
• The price range of $16.00 to $16.14 is within a normal range for market fluctuations.

Stakeholder Impact

• The sale of shares by a company officer may have a minor impact on investor sentiment, but is unlikely to have a significant impact on the share price due to the pre-arranged nature of the sale.

Key Dates

Keywords

Contineum Therapeutics, insider trading, Form 4, 10b5-1 plan, stock sale, Daniel S. Lorrain, CTNM, Chief Scientific Officer